A5016554000- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Cardiac Imaging and Diagnostics
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Palliative Care and End-of-Life Issues
- HER2/EGFR in Cancer Research
- Cancer, Lipids, and Metabolism
- Reproductive Biology and Fertility
- Cardiovascular Health and Disease Prevention
- Global Cancer Incidence and Screening
- Cancer survivorship and care
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Nutrition and Health in Aging
- Colorectal Cancer Treatments and Studies
- Advanced MRI Techniques and Applications
- Pain Management and Opioid Use
- Cardiovascular Disease and Adiposity
- Cardiovascular Function and Risk Factors
- Lymphoma Diagnosis and Treatment
- Ethics in Clinical Research
- Cardiovascular Health and Risk Factors
- Peripheral Artery Disease Management
Virginia Commonwealth University
2009-2025
Wake Forest University
2022
University Health System
2017
Abraxis (United States)
2009
University of Alabama at Birmingham
2009
Memorial Sloan Kettering Cancer Center
2009
Palmetto Hematology Oncology
2007
Virginia Commonwealth University Medical Center
1996-2002
BackgroundStatins taken for cardiovascular indications by patients with breast cancer and lymphoma during doxorubicin treatment may attenuate left ventricular ejection fraction (LVEF) decline, but the effect of statins on LVEF among no is unknown.MethodsA double-blind, placebo-controlled, 24-month randomized trial 40 mg atorvastatin per day administered to receiving was conducted within National Cancer Institute Community Oncology Research Program across 31 sites in United States. At...
PURPOSE Guidelines recommend cardiovascular (CV) risk assessment and counseling for cancer survivors. This study evaluated the automated heart-health (AH-HA) clinical decision support tool to promote provider-patient CV health (CVH) discussions in outpatient oncology. METHODS The AH-HA trial (WF-1804CD), coordinated by Wake Forest National Cancer Institute Community Oncology Research Program Base, randomized practices or usual care (UC) enrolled survivors receiving routine ≥6 months after...
Background Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood pathologic complete response (pCR) to chemotherapy. DNA methyltransferase inhibitors (DNMTi) can augment immune responses cancers, decreasing myeloid-derived suppressor cells (MDSCs) and increasing T lymphocyte responsiveness. We have shown that the DNMTi decitabine augments effectiveness immunotherapy using murine triple-negative cancer (TNBC) models. The primary...
Cancer treatment increases cardiovascular disease risk, but physical activity (PA) may prevent disease.
Adjuvant endocrine therapy (AET) improves outcomes in women with hormone receptor-positive (HR
1006 Background: Nanoparticle albumin-bound paclitaxel (nab-P) 260 mg/m 2 is superior to 175 (P) every 3 weeks (Gradishar et al., J Clin Oncol. 2005). Weekly uninterrupted P more effective than q3wk in MBC (Seidman 2008). Bevacizumab (bev) nearly doubles response rate and time progression (TTP) when added as 1st line therapy for (Miller N Engl Med. 2007). Methods: This open-label, phase II study randomized patients (pts) nab-P at (arm A) versus q2wk with filgrastim B) 130 weekly...
Thromboangiitis obliterans (TAO) is a nonatherosclerotic, nonnecrotizing, nonspecific, segmental inflammatory obliterative vasculitis, characterized by decreased flow to the distal extremities and increased risk of amputation. While smoking cessation viewed as critical successful treatment, various therapeutic options have been employed. many treatment regimens seek diminish platelet function, there are relatively few studies function in this disease entity even fewer that offered evidence...
Abstract Background: Higher levels of stromal tumor-infiltrating lymphocytes (sTILs) in breast cancers are associated with increased likelihood pathologic complete response (pCR) to chemotherapy and improved outcomes. DNA methyltransferase inhibitors (DNMTi) can augment immune responses by upregulating tumor antigen MHC expression, decreasing numbers activity myeloid derived suppressor cells (MDSC), increasing responsiveness T lymphocytes. We have shown that the DNMTi decitabine augments...
Both HCV and HIV are common in haemophiliacs previously treated with non-viral-inactivated clotting factor concentrates. Because of increased bleeding risks, little data available on the safety percutaneous outpatient liver biopsy (LBx) impact coinfection this population. This study aims at reporting our experience LBx a cohort infected describe spectrum disease coinfection. A retrospective review consecutive patients haemophilia who underwent was performed. All were positive for RNA by...
Less than 50% of physicians know the resuscitation wishes their patients and only a small fraction have completed "do not resuscitate" (DNR) orders before death. One common reasons given by is that process "getting DNR" takes too long, some authorities suggested additional reimbursement needed. The purpose this study to assess how long DNR education consent actually in practice. Our group was convenience sample consecutive seen experienced oncologists community academic practice setting....
Abstract Background: Treatment for premenopausal women with high or intermediate risk hormone receptor (HR)+ breast cancer (BC) includes the concurrent use of ovarian function suppression (OFS) and an aromatase inhibitor (AI) to induce near complete estrogen deprivation (NCED). The long-term cardiovascular (CV) sequela treated NCED is unknown. Premature menopause in non-cancer populations associated CV disease. CROWN study (CaRdiac Outcomes With Near deprivation) will sophisticated imaging...
11123 Background: For the 10% of women diagnosed with cancer in reproductive age, health (RH) is a critical component oncologic survivorship. RH includes oncocontraception (OC), oncofertility (OF) and sexuality. Guidelines segregate these components resulting fragmented care management. Methods: The EROS trial clustered randomized performed at 17 NCI Community Oncology Research Program (NCORP) sites (including 8 NCORP 9 Minority/Underserved sites) from 2016-2023. Eligible subjects included...
11124 Background: The average recruitment of minority subjects in oncology trials is 4%. ECOG-ACRIN EROS trial was designed to be inclusive by inviting Minority/Underserved NCI Community Oncology Research Program (MU-NCORP) sites first, with remaining fulfilled NCORP sites. Our objective examine if the study recruited more than 4% patients, and MU-NCORP provided higher rates Methods: a clustered randomized performed at 17 (NCORP) (including 8 9 sites) from 2016-2023. Eligible included...
Abstract Background To understand how body composition in those with elevated mass index impacts left ventricular function decline during cancer treatment, we determined the association between baseline (BMI), intra-abdominal adipose tissue (IAT) and subcutaneous (SAT) to 3-month ejection fraction (LVEF) change among women receiving potentially cardiotoxic chemotherapy for breast cancer, lymphoma, or sarcoma. Methods Women underwent chemotherapy, such as doxorubicin, cyclophosphamide,...
TPS12146 Background: Treatment for premenopausal women with high/intermediate risk hormone receptor (HR)-positive breast cancer (BC) includes the concurrent use of ovarian function suppression (OFS) and an aromatase inhibitor (AI) to induce near-complete estrogen deprivation (NCED). The long-term cardiovascular (CV) sequela treated NCED is unknown. Premature menopause in non-cancer populations associated CV morbidity. Given overall injury BC treatment future life-years these women, impact...
Abstract Purpose To examine the differential effect of non- and anthracycline-based chemotherapy on fatigue over 12 months post-diagnosis among breast cancer survivors. Methods This study is based a prospective Wake Forest NCI Community Oncology Research Program (NCORP) multicenter cohort (WF-97415) women with stage I to III non-cancer controls. Analyses compared those: 1) receiving, or 2) not receiving anthracycline chemotherapy, 3) aromatase inhibitors (AIs) without 4) comparator group...